By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bionor Pharma ASA 

6701 Democracy Boulevard
Suite 300
Bethesda  Maryland  20817  U.S.A.
Phone: 301-571-9493 Fax: 301-564-9619



Company News
Bionor Pharma ASA's Phase II Vacc-4x Data Published In The Lancet Infectious Diseases 2/11/2014 9:32:10 AM
Bionor Pharma ASA Appoints Anker Lundemose New VP and CEO 1/29/2013 7:02:25 AM
Bionor Pharma ASA Release: Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial 12/5/2012 9:37:03 AM
Bionor Pharma ASA Release: Analysis of Immune Responses in Patients Treated With Vacc-4x Supports Further Development 9/12/2012 10:05:37 AM
Bionor Pharma ASA Release: Study of Vacc-4x Combined With Celgene (CELG)'s Revlimid® (lenalidomide) in HIV Patients With Impaired Immune System Approved to Begin 8/13/2012 8:48:18 AM
Bionor Pharma ASA's Therapeutic HIV Vaccine Vacc-4x Improves Quality of Immune Responses in HIV Patients, Resulting in Long-Term Reduction in Viral Load and Potential for Periodic "Boosts" That Could Result in New Treatment Option for People Living With HIV/AIDS 7/20/2012 9:18:04 AM
HIV- and Oncology Research Expert Professor Gus Dalgleish Joins Clinical Advisory Board Bionor Pharma ASA 7/17/2012 9:12:52 AM
GLOBVAC Awards Bionor Pharma ASA US $1.7 Million to Advance Research Towards an HIV Cure Using Vaccine Vacc-4x 7/9/2012 8:56:57 AM
Bionor Pharma ASA Release: International Patent Application Submitted for the Therapeutic and Potentially Preventive Vaccine Vacc-HIV, Combining Bionor's Vacc-4x and Vacc-C5 6/7/2012 9:01:03 AM
Bionor Pharma ASA Release: International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus 6/7/2012 8:58:30 AM